HCV Testing Strategies and New Patient Identification in The United States

Presented at: Commercial and Clinical Debates in Hepatitis C
NY, NY
April 16, 2013
Chronic Condition X

- Lifetime mortality between 20% and 30% from direct causes of disease.
- Hypothesized ancillary effects may increase mortality to as high as 50%.
- Affected population has many competing health, social, and economic problems to consider.
- Treatment is difficult, uncomfortable for the patient, and usually fails.
- Successful treatment is associated with a substantial decrease in mortality and enhanced patient reported quality of life.
BORN FROM 1945 TO 1965?

AMERICANS BORN DURING THESE YEARS HAVE THE HIGHEST RATES OF HEPATITIS C.

Talk to your doctor about getting tested. Early detection can save lives.

www.cdc.gov/knowmorehepatitis
Questions

- Is population based testing cost-effective?
- How sensitive is the cost-effectiveness to important model assumptions?
- What are potential testing implementation strategies?
- What are future opportunities and venues to enhance testing?
## Is Population Testing Cost-Effective?

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>QALYs</th>
<th>Costs ($b)</th>
<th>ICER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rein, et al (2012)</td>
<td>PR</td>
<td>348,800</td>
<td>5.5</td>
<td>$15,700</td>
</tr>
<tr>
<td>Coffin, et al (2012)</td>
<td>PR</td>
<td>213,883</td>
<td>0.9</td>
<td>$4,438</td>
</tr>
<tr>
<td>Coffin, et al (2012)</td>
<td>DAA</td>
<td>570,222</td>
<td>19.8</td>
<td>$34,794</td>
</tr>
<tr>
<td>Liu, et al (2013)</td>
<td>DAA</td>
<td>562,023</td>
<td>37.7</td>
<td>$68,980</td>
</tr>
<tr>
<td>Eckman, et al (2013)</td>
<td>DAA</td>
<td>856,986</td>
<td>40.0</td>
<td>$47,276</td>
</tr>
</tbody>
</table>
Is Population Testing Cost-Effective?

Cost = $37,458 \times Q + 13.628

R² = 0.3544

Yes

Cost/Person

QALY/Person

Rein, PR

Rein, DAA

McGarry, DAA

Coffin, PR

Coffin, DAA

Liu, PR

Liu, DAA

Eckman, DAA

McEwan, 2013
Potential Impact - Application

- Population Size
- Prevalence
- Viral Clearance
- Expected Mortality Rate Without Treatment
- Proportion Tested
- Proportion Treated
- SVR
What are potential testing implementation strategies?

• Electronic Health Record Prompts
  • NYC
  • Boston

• Direct Mail to Patient
  • Michigan

• Point of Care
  • Alabama, Primary Care
  • Alabama, Emergency Department
Testing Implementation – Opportunities

• Standing Order Protocols (SOP)
  • No examples in HCV
  • Influenza experience

• National Quality Indicators
  • NCQA HEDIS measures in early development
  • Patient centered quality indicators
    – Screening
    – Confirmation and patient evaluation
    – Vaccination
Testing Implementation – Opportunities

• Public Health
  • Federally Qualified Health Centers
  • Public Health Prevention Fund
  • Correctional Settings

• State Medicaid Programs
  • Medicaid expansion
  • Medicaid plan participation requirements

• State Health Insurance Exchanges
  • Incorporation into minimum benefit package
Thank You!

David Rein, rein-david@norc.org